NCT05413850 2026-03-02
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT06785636 2025-11-14
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT06190899 2025-03-21
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT03490032 2020-11-17
PROfind
Advanced Accelerator Applications
Phase 1/2 Completed
NCT02606123 2018-03-01
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
ESSA Pharmaceuticals
Phase 1/2 Terminated
NCT00895466 2009-05-08
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
Pepscan Therapeutics
Phase 1/2 Unknown